In contrast, ERKs1 and 2, and their active phosphorylated forms (p-ERK1/2) were present in higher levels in metastatic breast cancer than primary breast cancer, and at very low levels in benign breast diseases (Figure 1C). Here, MAPK3 is linked to breast fibrocystic disease.